Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 31;17(2):sfae013.
doi: 10.1093/ckj/sfae013. eCollection 2024 Feb.

Moderator's view: after SGLT2i and MRA antagonists, where do we go?

Carmine Zoccali  1   2   3 , Jürgen Floege  4
Affiliations
Review

Moderator's view: after SGLT2i and MRA antagonists, where do we go?

Carmine Zoccali et al. Clin Kidney J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

J.F. is the ad interim Editor-in-Chief of CKJ and C.Z. is member of the CKJ Editorial Board.

References

    1. Yu JH, Park SY, Lee DYet al. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Res Clin Pract 2022;41:136. 10.23876/j.krcp.22.001. - DOI - PMC - PubMed
    1. Rovin BH, Ayoub IM, Chan TMet al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int 2024;105:31–4. Available from: https://pubmed.ncbi.nlm.nih.gov/38182299/. - PubMed
    1. van Gelder T, Lerma E, Engelke Ket al. Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. Exp Rev Clin Pharmacol 2022;15:515–29. Available from: https://pubmed.ncbi.nlm.nih.gov/35763288/. - PubMed
    1. Wang Y, Al-Dakkak I, Garlo Ket al. Atypical hemolytic uremic syndrome treated with Ravulizumab or Eculizumab: a claims-based evaluation of health care resource utilization and clinical outcomes in the United States. Kidney Med 2023;5:100683. 10.1016/j.xkme.2023.100683. - DOI - PMC - PubMed